Associated Companies

In Spring 2009, Redoxis founded the company ProNoxis AB, with funding from LUBio AB and Karolinska Development AB. ProNoxis will continue the preclinical development of the Redoxis “NOX2 project” for treatment of rheumatoid arthritis. For further information, please contact Karin Bryder, CEO Pronoxis AB.